Evethe grouwth the strongest resstance to thaldomdehad ahgher response fee.a different prospectve subgrouanalyss, the benefts of startng lenaldomde therapy at frst relapse had been assessed by comparng outcomes wth lenaldomde plus dexamethasone versus dexamethasone alone amongst patents whohad receved one particular versus two pror therapes.one hundred Among the 248 of 692 patents whohad receved just one pror treatment, people assgned to second lne lenaldomde plus dexamethasonehad a sgnfcantlyhgher ORR thathose recevng dexamethasone alone.Amid the 456 patents whohad receved two pror therapes, individuals treated wth lenaldomde plus dexamethasone alsohad a sgnfcantlyhgher ORR thathose taken care of wth dexamethasone alone.Comparng patents who receved lenaldomde plus dexamethasone as second lne versus later salvage treatment, the ORR appearedhgher wth early therapy.
Ahgher proportoof patents recevng 2nd lne therapyhad prevouslyhad SCT, whereas far more patents recevng later on salvage therapyhad prevously receved thaldomde and bortezomb.further subanalyses of MM 009 and MM 010, Foa and colleagues reported that amid 154 patents wth gA dsease at baselne, lenaldomde plus dexametha sone was assocated wth a selelck kinase inhibitor sgnfcantlyhgher ORR thadexamethasone alone.101 The CR fee patents wth gA dsease who had been treated wth lenaldomde plus dexamethasone, versus dexamethasone alone, was 18.1% and 0%, respec tvely.Smarly, patents wthout gA dsease at baselne, lenaldomde plus dexamethasone acheved ahgher ORR in contrast wth dexamethasone alone.A separate analyss demonstrated that the superorty of lenaldomde plus dexamethasone in contrast wth dexamethasone alone was ndependent of baselne ECOG overall performance status.
102 ths analyss, patents wth aECOG scores of 0 or 1had sgnfcantlyhgher ORR wth lenaldomde plus dexamethasone compared wth dexamethasone selleck alone.Also, age dd not determne response to lenaldomde, wth yet another subanalyss showng that ORR was sgnfcantlyhgher for lenaldomde plus dexamethasone in contrast wth dexamethasone alone for patents aged 65ears, 65 75ears, and 75ears.103 a pooled subgrouanalyss of 682 patents wth serum creatnne amounts of ?2.5 mg dL at baselne, lenaldomde plus dexamethasone sgnfcantly mproved response price in contrast wth dexamethasone alone patents wth standard renal functoand those wth md and moderate renal mparment104.The ORR was not sgnfcantly dfferent betweelenaldo mde plus dexamethasone and dexamethasone alone the 28 patents wth significant renal mparment, wth CR rates followng a smar trend to ORR.
Fnally, a posthoc analyss of data in the MM 009 and MM 010 trals ndcated that dexamethasone dose reductons mproved the effcacy of lenaldomde plus dexamethasone therapy in contrast wth patents who contnued to receve dexamethasone at the planned dose.105 Patents assgned to lenaldomde plus dexamethasone and

whohad a subsequent dexamethasone dose reductoexperenced a sgnfcantlyhgher ORR and CR rate compared wth patents who contnued to receve the typical dexamethasone regmecombnatowth lenaldomde.